West Houston Heart Center - Humayun Naqvi, MD, MBA

West Houston Heart Center - Humayun Naqvi, MD, MBA We are focused on providing comprehensive, guideline directed, compassionate cardiovascular care in the west Houston area.

For you next appointment, please visit:

https://health.healow.com/westhoustonheart Humayun Naqvi, MD, MBA, FACC, and his staff at West Houston Heart Center in Houston, Texas, provide the expert care their patients require to overcome the challenges of heart disease. Dr. Naqvi also specializes in preventative cardiology, focusing on minimizing risk factors for heart disease and preventing worsenin

g illness. Services at West Houston Heart Center utilize the latest diagnostic equipment and testing modalities to provide evidence-based treatments that offer excellent results for cholesterol management, elevated blood pressure, congestive heart failure, metabolic syndrome, heart attack, atrial fibrillation/arrhythmias, peripheral vascular disease, and aortic aneurysm. Procedures and diagnostic studies available through West Houston Heart Center include nuclear stress testing, left and right heart catheterization, transesophageal echocardiogram, dobutamine stress echo, loop recorder placement, cardiac CT, and ankle-brachial index (ABI) studies. Dr. Naqvi and his staff combine highly advanced medical technologies and techniques with personalized, patient-centered healthcare that creates an atmosphere of trust and mutual respect. As a Preventive Cardiology specialist, Dr. Naqvi also offers cardiac evaluations and customized strategies for maintaining optimal heart health regardless of age. Schedule an evaluation at West Houston Heart Center today by calling the office or requesting an appointment using their convenient and secure online service.

05/26/2026

In September 1955, President Eisenhower’s massive heart attack dominated national headlines for weeks. At the time, cardiovascular disease carried an air of inevitability; effective therapies were limited and public understanding was rudimentary.

Fast-forward seven decades and the picture has transformed through compounding, largely invisible progress. Age-adjusted cardiovascular disease death rates have fallen roughly 60% since 1950 (CDC). Acute myocardial infarction mortality dropped 89% between 1970 and 2022 (354 to 40 per 100,000), while ischemic heart disease mortality fell 81% (JAHA, 2025). Overall heart disease deaths declined 66% over the past fifty years, with the burden shifting from sudden, lethal events toward more manageable chronic phenotypes.

These gains did not arrive via any single breakthrough that captured sustained public attention. They accumulated through decades of incremental advances: better blood-pressure control, smoking cessation, statins, antiplatelet therapy, timely reperfusion, and refined risk stratification. Each step was modest in isolation; together they produced one of the largest public-health victories in modern medicine.

As cardiologists we witness the downstream effects daily—patients who would once have died now live full decades. Yet because the progress is slow and the absence of catastrophe rarely makes headlines, it is easy to underestimate how far we have come. The visible story remains the heart attack; the durable story is the quiet compounding of prevention and treatment that has steadily reduced its lethality.

What fraction of today’s clinical outcomes would have been considered impossible in 1955, and how much of that shift do we still treat as ordinary?



https://substack.com/

05/25/2026

We often dismiss the battles between big tech and traditional healthcare as 'childish' squabbles over territory. But what if this isn't a petty fight, but a calculated, systemic dismantling of existing healthcare structures, driven by profound profit motives that shareholders are actively rewarding?

The market’s immediate positive response to job losses due to AI isn't an anomaly; it's a clear signal that the underlying economic model values automation over human capital. To frame this as mere childishness misses the strategic, cold calculation at play. The question isn't *if* AI will replace certain roles, but *how* we, as physicians and leaders, will respond to the systemic incentives that drive this replacement. Are we merely spectators in a South Park episode, or are we actively shaping the future of care delivery amidst these shifts?

Challenge your assumptions on EP 24 - Four Headlines Every Doctor Fears: Amazon GLP-1s, AI Replacing MDs, End of the Pen. https://2docs1mic.com



https://2docs1mic.com

https://substack.com/

05/20/2026

The market's reaction to AI replacing jobs reveals a crucial insight for physician-operators: profitability, not struggle, is the driver. When companies announce AI-driven workforce reductions, their stock often surges. This isn't about failing businesses; it's about a fundamental economic incentive for efficiency and increased margins.

This trend is directly impacting healthcare's 'retailization.' Big tech isn't entering medicine purely for patient benefit; they're optimizing for profit. As physician-operators, we must understand that the threat isn't just AI replacing tasks; it's a systemic shift where the value proposition of human labor is being re-evaluated through a purely financial lens. Our leadership role is now about navigating this economic reality, not just clinical practice. We must proactively shape how AI integrates, ensuring it serves patients, not just shareholders.

Hear our full take on EP 24 - Four Headlines Every Doctor Fears: Amazon GLP-1s, AI Replacing MDs, End of the Pen. https://2docs1mic.com



https://2docs1mic.com

https://substack.com/

05/19/2026

AI will transform medicine and operations, but it still can't supply what the world is shortest on: common sense. Algorithms optimize protocol adherence, revenue-cycle logic, and utilization review. They can flag a missed gap in care or an unusual billing pattern. Yet knowing when a patient-specific variable, an unmodeled payer exception, or a human workflow friction invalidates the model's recommendation—that judgment remains irreplaceably human.

The systems that actually perform are those engineered to put common sense at the decision layer: staff who can read the data and the moment, leadership that designs escalation paths for exceptions, and governance that refuses to outsource wisdom. AI is infrastructure. Common sense is the operating system.



https://substack.com/

05/19/2026

Charlie Munger told this story about honeybees and I haven't stopped thinking about it.

Karl von Frisch discovered that bees communicate through a "waggle dance" — direction, distance, precise location of nectar. Extraordinary biological engineering.

But von Frisch ran one critical experiment. He placed the nectar source directly above the hive. Straight up.

The bee returned. And did nothing.

No dance. No signal. No attempt to communicate something her nervous system wasn't built to compute.

Munger called this perfect intellectual honesty.

He then asked: how many people in your organization would do the same? How many executives, consultants, or colleagues feel compelled to produce a confident answer even when operating well outside their competence?

In medicine, we've built training that rewards the opposite. Uncertainty is weakness. Silence signals incompetence. The attending who says "I don't know" is penalized; the one who confidently guesses is promoted.

The bee understood something we've systematically unlearned: a wrong signal from a position of confidence is far more dangerous than no signal at all.

The physician who says "I don't know — let me find out" is not your liability. The one who never says it is.



https://substack.com/

05/18/2026

The notion that AI's future is inherently 'uncontrollable' is a dangerous fallacy, designed to absolve us of responsibility. We are not spectators; we are the architects, the data providers, and the policy shapers. The 'paradox' isn't about AI's autonomy, but our collective will to govern its development and deployment. Every algorithm is a reflection of human choices – in data selection, weighting, and ethical guardrails. To claim we can't control it is to surrender agency, allowing commercial interests or naive optimism to dictate medicine's technological trajectory. The real question is: are we willing to exert the necessary control, establishing robust frameworks for accountability, transparency, and patient-centric design, even when it slows progress or challenges profitability? Or will we accept the narrative of inevitable, unchecked progress? Join us as we push back on this premise in EP 22 - The AI Paradox: Debating a Future We Can't Control? at https://2docs1mic.com.



https://2docs1mic.com

https://substack.com/

05/13/2026

AI in medicine is a double-edged sword. On one hand, its capacity to accelerate drug discovery and enhance diagnostic precision is undeniable. The mechanism is clear: vast data processing power uncovers patterns and simulates outcomes far beyond human capability. The implication for patients is revolutionary treatments and earlier disease detection.

However, the moment AI steps into automated prescribing or insurance decision-making without robust, human-driven oversight, we introduce systemic risk. Algorithmic bias, inherent in the training data, can disproportionately affect vulnerable populations. The mechanism here is the propagation of existing inequities through 'efficient' automated systems. The implication? Patient safety is compromised, and the ethical bedrock of medicine erodes.

We must demand transparency and accountability, ensuring AI remains a tool for augmentation, not a replacement for clinical judgment. Failing to do so risks a future where convenience trumps care. Listen to EP 24 - Four Headlines Every Doctor Fears: Amazon GLP-1s, AI Replacing MDs, End of the Pen, to understand the full scope. https://2docs1mic.com



https://2docs1mic.com

https://substack.com/

05/12/2026

40–50% of patients stop their statin within the first year. This is not irrational behavior—it is the predictable output of how the medial prefrontal cortex assigns value to future cardiovascular risk versus present-day side effects and daily hassle.

When patients weigh “my heart in 10 years” against “leg pain today,” the medial PFC often discounts the distant benefit steeply. That is not a knowledge gap. It is a valuation problem. Standard adherence lectures ignore this mechanism and therefore fail.

Effective interventions must change the subjective value calculation: immediate feedback on plaque regression, tangible risk visuals tied to the patient’s own imaging, or reframing the daily pill as protecting something the patient already values highly (grandchildren, golf, autonomy).

Until we address the valuation circuitry, discontinuation rates will remain a fixed feature of statin therapy rather than a fixable bug.



https://substack.com/

05/11/2026

The debate isn't *if* AI transforms clinical diagnostics, but *how* we mitigate its inherent biases. AI's prowess in pattern recognition, from radiology to pathology, promises unprecedented speed and accuracy in identifying subtle disease markers. This mechanism will undoubtedly lead to earlier diagnoses and more precise treatment pathways. However, the models are only as unbiased as the data they're trained on. If our datasets reflect existing healthcare disparities, AI will merely amplify them, embedding systemic inequities into the very fabric of future medicine. Physician oversight isn't just about ethical review; it's about understanding the data provenance and the potential for algorithmic harm. Are we prepared to scrutinize AI's 'evidence' as rigorously as we do human judgment? Listen to our deep dive on EP 22 - The AI Paradox: Debating a Future We Can't Control? at https://2docs1mic.com.



https://2docs1mic.com

https://substack.com/

05/10/2026

We spend 10-15 years training physicians to operate inside a system.

Zero years training them to evaluate whether that system is worth operating inside.

Dalio would call this a failure of radical transparency — we never show trainees how the financial and power architecture actually works.

Taleb would call it fragility by design — practitioners with no ownership stake, no upside, and unlimited downside exposure.

The most important question a resident isn't asked:

"If you owned this practice, would you run it this way?"

That question changes everything. It forces mechanism-level thinking. It forces skin-in-the-game consciousness before the contracts are signed.

The physicians reshaping healthcare delivery right now aren't the ones who optimized best within the system.

They're the ones who asked that question early enough to do something about it.



https://substack.com/

Address

1140 Business Center Drive Ste 300
Houston, TX
77043

Opening Hours

Monday 8am - 5pm
Tuesday 8am - 5pm
Wednesday 8am - 5pm
Thursday 8am - 5pm
Friday 8am - 5pm

Telephone

+18324003957

Website

Alerts

Be the first to know and let us send you an email when West Houston Heart Center - Humayun Naqvi, MD, MBA posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to West Houston Heart Center - Humayun Naqvi, MD, MBA:

Shortcuts

Featured

Share

Category